Thromboelastography (TEG) is used to diagnose perturbations in clot formation and lysis that are characteristic of acute traumatic coagulopathy. With novel functional fibrinogen (FF) TEG, fibrin-and platelet-based contributions to clot formation can be elucidated to tailor resuscitation and thromboprophylaxis. We sought to describe the longitudinal contributions of fibrinogen and platelets to clot strength after injury, hypothesizing that low levels of FF and a low contribution of fibrinogen to clot strength on admission would be associated with coagulopathy, increased transfusion requirements, and worse outcomes.
T he accurate identification and treatment of acute traumatic coagulopathy (ATC) is of utmost importance in the care of trauma patients because these patients have significant associated morbidity and mortality. 1Y4 Indeed, the 25% to 33% of severely injured patients who experience ATC often present with uncontrolled hemorrhage and have a high incumbent mortality unless rapid hemostatic resuscitation is instituted. Because of this, the timely identification and treatment of ATC is crucial. Viscoelastic testing via thromboelastography (TEG) is poised to replace traditional plasma-based tests (international normalized ratio [INR] , partial thromboplastin time [PTT] ) in the diagnosis of perturbations in clot formation and lysis characteristic of ATC as well as the guidance of resuscitation and thromboprophylaxis. 5Y10 TEG measures clot formation and lysis in real time in a sample of whole blood by producing a characteristic tracing from which several parameters are identified.
Clot formation is the end result of a sequential protease activation cascade resulting in platelet activation and fibrin deposition and cross-linking. The TEG parameter maximal amplitude (MA) is purported to be a measure of total clot strength, but until recently, the relative contributions of platelets and fibrin to this clot strength have been unknown. Historically, the function of fibrinogen was represented by the TEG parameters kinetic time and > angle because they are measures of the rapidity of fibrin buildup and cross-linking, but the correlations between these measures and fibrinogen levels measured by the traditional von Clauss assay 11 have been suboptimal. 12, 13 remaining clot strength (MA) is caused by the fibrin contribution. 14, 15 From this FF TEG, two important parameters are obtained. The first, FF MA (FF MA), is the maximal clot strength caused by the polymerization of fibrin alone. The second, FF level (FLEV), is calculated by analytical software through a transformation of the FF MA to approximate the concentration of ''functional'' fibrinogen contained in the sample. 16 This crucial differentiation between platelet and fibrin contributions to clot strength can assist in tailoring both early resuscitation and later thromboprophylaxis. We sought to explore the longitudinal relative contributions of fibrinogen and platelets to clot strength after injury, hypothesizing that a low FLEV and a low contribution of fibrinogen to clot strength on admission would be associated with coagulopathy, transfusion requirements, and worse outcomes.
PATIENTS AND METHODS
Longitudinal plasma samples were prospectively collected from 251 critically injured trauma patients at a single Level 1 trauma center on arrival and at 2, 3, 4, 6, 12, 24, 48, 72, 96 , and 120 hours after admission to a Level I urban trauma intensive care unit (ICU).
Our methodology for collection of whole blood for viscoelastic testing has been described previously. 17 Briefly, admission samples were collected via initial placement of a 16 gauge or larger peripheral intravenous line; subsequent samples were collected via indwelling arterial catheters. Standard laboratory vacuum-sealed tubes containing 3.2% (0.109 mol/L) sodium citrate were used for all draws. After a waiver of consent was applied for initial blood draws, informed consent was obtained from all patients, as approved by the University of California Committee on Human Research. A total of 603 samples were analyzed on 251 patients. Demographics, resuscitation data, clinical laboratory results, and outcomes were collected in parallel. Point-of-care TEG was performed to assess viscoelastic properties of clot formation with the TEG 5000 (Haemonetics, Niles, IL) immediately after sample collection. One mL of citrated whole blood was added to a manufacturerstandardized vial containing the clotting activator kaolin and mixed. Following this, 340 HL was transferred from the kaolin vial to the TEG cup, warmed to 37-C, and recalcified with 20 HL of 0.2-mol/L CaCl2. For the FF TEG, 500 HL of citrated blood was added to the FF vial (kaolin + glycoprotein IIb/IIIa antagonist) and mixed; 340 HL was then transferred to the TEG cup and warmed and recalcified as described earlier. In parallel, plasma fibrinogen concentration was assayed by the von Clauss method, 11 and plasma-based standard coagulation measures were performed. Platelet contribution to clot strength was calculated as MA TEG j MA FF = MA platelets . Percentage contributions of FF (%MA FF ) and platelets (%MA platelets ) were calculated as each respective MA divided by the overall kaolin TEG MA. Coagulopathy was defined by admission INR equal to or greater than 1.3. Thrombocytopenia was defined by platelets equal to or less than 200. Multiorgan failure was defined using the Denver Postinjury Multiple Organ Failure Score.
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Data are presented as mean (SD), median (interquartile range [IQR]), or percentage; univariate comparisons were made using Student's t test for normally distributed data, Wilcoxon rank-sum or Kruskal-Wallis testing for skewed data, and Fisher's exact test for proportions. Intergroup comparisons between multiple groups were only judged significant when corrected for multiple comparisons using a standard Bonferroni correction. Linear regression was used to assess correlations between prospectively collected TEG values and laboratory values. Cox proportional hazards regression was used to identify predictors of mortality. An > = 0.05 was considered significant. All analysis was performed by the authors using Stata version 12 (StataCorp, College Station, TX).
RESULTS
The 251 patients were a standard trauma population, with a median age of 35 years (24Y50 years), 80.7% male, and blunt mechanism of injury in 52.6%. A median Injury Severity Score (ISS) of 9 and median admission base deficit of j3.1 (j8.7 to 1.5) reflected an injured population ( Table 1 ). The median INR on admission was 1.1; coagulopathy (INR Q 1.3) was present in 16.7% of the patients. Median admission platelet count and fibrinogen were within respective normal ranges (platelet, Table 2 ). The patients in the lowest FLEV percentile were younger than those in the highest FLEV percentile (''low'' median age, 26.5 years; IQR, 23Y41; ''high'' median age, 40 years, IQR, 33Y51.5; p G 0.017 corrected for multiple comparisons) but had no statistically significant differences in injury severity or admission base deficit (all p 9 0.05, Table 2 ).
However, those in the lowest admission FLEV percentile had the highest rate of coagulopathy (25%) and thrombocytopenia (20.8%), and not surprisingly, the lowest von Clauss fibrinogen levels (159 mg/dL; IQR, 139Y201; p G 0.017 corrected for multiple comparisons; all p G 0.05; Table 2 ). Patients in both the lowest and the highest admission FLEV percentiles had higher pRBC transfusion requirements (29% in low, 14.3% in mid, 33.3% in high; p = 0.030). However, the patients in the lowest FLEV percentile had the highest plasma transfusion requirements (22.4% in low, 8.3% in mid, 5.5% in high; p = 0.033). Those patients in the lowest FLEV percentile trended toward higher mortality at discharge (12% in low, 9.4% in mid, 5.4% in high, nonsignificant; p = 0.658; Table 2 ). Higher admission FLEV predicted reduced mortality in an unadjusted model (hazard ratio, 0.991; p = 0.005), whereas von Clauss fibrinogen did not (hazard ratio, 1.00, p = 0.601).
Next, we compared patients with low, intermediate, and high clot strength by CK MA percentiles (mean CK MA, 57.7 mm vs. 65.4 mm vs. 72.6 mm; p = 0.0010, Supplement 1, http://links.lww.com/TA/A353). The 51 patients with the lowest clot strength (mean CK MA, 57.7) were younger (mean age, 36.1 vs. 37.3 vs. 44.9, p G 0.017 corrected for multiple comparisons) but had no significant difference in mean injury severity (13.2 vs. 10.1 vs. 9.9, p = 0.1493, Supplement 1, http://links.lww.com/TA/A353) than those patients with intermediate or high clot strength. As expected, those with the lowest clot strength had the highest percentage with coagulopathy (26.1% vs. 11.3% vs. 8.9%, p = 0.0470) but no statistically significant differences in transfusion needs (24-hour transfusion of pRBC/FFP, 28.2% vs. 21.4% vs. 27.9%; p = 0.5990; Supplement 1, http://links.lww.com/TA/A353) compared with those with intermediate or high clot strength. We then stratified by high and low FLEVs, split at the mean for patients in each percentile of clot strength (Table 3) . Notably, the 24 patients with low clot strength and low FLEV trended toward higher rates of coagulopathy than those with low clot strength and high FLEV (34.8% vs. 10.0%, p = 0.0760). In addition, they had significantly worse outcomes, requiring more transfusion of RBC/FFP in 24 hours (40.9% vs. 4.8%, p = 0.0090), had longer ICU stays (median, 1 day vs. 0 day, p = 0.0089), had fewer ventilator-free days (median, 27 days vs. 28 days, p = 0.0172), and trended toward a higher mortality (26.1% vs. 4.8%, p = 0.0970, Table 3 ). However, the patients with normal and high clot strength similarly stratified by FLEVs had no significant differences in coagulopathy, transfusion, or mortality (Supplement 2 and 3, http://links.lww.com/TA/A354; http://links.lww.com/TA/A355).
Following this, we calculated the percent contribution of fibrin to clot strength (%MA FF ) and the percent contribution of platelets (%MA platelets ) to clot strength at all time points after injury as described in the Patients and Methods section and Fig. 2 ). In contrast, %MA FF increased over time and stabilized at 72 hours (30.6% at 0 hour, 43.8% at 72 hours; Fig. 2 ).
DISCUSSION
Fundamental hemostatic capacity can be attributed to a combination of the rapidity of formation, absolute strength, and breakdown of clot. These mutual determinants of clot formation (or failure thereof ) account for the dynamic spectrum that spans from thrombosis to hemorrhage. Fibrin and platelets are the primary contributors to the absolute clot strength, which is represented by the TEG parameter MA, yet until now the relative contribution of fibrin deposition to clot strength over time after injury has been unknown. In addition, knowledge regarding the relative contribution of platelets to hemostasis has been missing. These crucial knowledge gaps may contribute to the polar differences in international resuscitation practices and thromboprophylaxis. Addressing these unknown relative contributions of fibrinogen and platelets to clot strength after injury are of critical importance for evidence-based guidance of early resuscitation and later thromboprophylaxis, 21 given opposing fibrinogen-based European and platelet-based US resuscitation practices.
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With the addition of the TEG FF test, novel differentiation of fibrin-versus platelet-based clot dynamics can assist in tailoring both early resuscitation and later thromboprophylaxis. Our data confirm the recently published work by Harr et al., 12 suggesting that FLEVs correlate with standard fibrinogen levels better than the historic TEG measures of fibrin buildup and cross-linking (kinetic time and > angle). In addition, we found that patients with low admission FLEVs are more commonly coagulopathic and require more transfusions, suggesting a role for FF testing in the evaluation of ATC and the future prediction of transfusion needs. Most importantly, patients with higher admission FLEVs had reduced mortality, whereas patients with higher von Clauss fibrinogen did not. In fact, for a 1-mg/dL increase in FLEVs, there was a 1% decrease in the risk of mortality at discharge (hazard ratio, 0.991, p = 0.005). This new functional measurement may better predict mortality in realtime compared with standard laboratory fibrinogen levels.
Notably, in the stratification of patients into low, intermediate, and high clot strength, the finding that only in patients with the lowest clot strength does a low FLEV associate with coagulopathy, transfusion needs, and worse outcomes (without a difference in injury severity) suggests that the level of FF is of critical importance in patients with an overall deficiency in the strength of the clot. Injured patients with poor overall clot strength and a low FLEV may be the appropriate target population for transfusion with fibrinogen containing products.
We next demonstrated that in injured patients, both coagulopathy and need for plasma transfusion were associated with a lower percent contribution of fibrinogen to clot strength.
In addition, a higher admission percent contribution to clot strength predicted reduced mortality. For a 1% increase in the contribution of fibrinogen to clot strength, there was a 12.9% decrease in the risk of mortality at discharge (hazard ratio, 0.871, p G 0.001). These findings suggest a major importance of fibrinogen to the hemostatic function of the clot. However, despite the importance we found of fibrinogen function in relation to coagulopathy, transfusion needs, and mortality, we demonstrated that platelets have a larger contribution to clot strength at all time points after injury. While specific perturbations of fibrinogen and platelets and their role in the functional dynamics of ATC are not completely characterized, our findings suggest that attention to the relative contribution of fibrinogen and platelet function should guide both early resuscitation and later thromboprophylaxis.
As with other single-center prospective studies of traumatic coagulation, several limitations exist. Fibrinogen accounts for approximately 20% of clot strength in normal individuals; 12, 21 however, our study demonstrates that after injury, fibrinogen accounts for 30.5% of clot strength on admission which increased to 43.5% during the ensuing 5 days. Like all physiologic responses after injury, the injury response is very different from a normal population, and to characterize biomarkers such as FF, we must characterize them in a trauma population in relation to outcomes. Fibrinogen is an acute phase reactant and may be on the whole higher in patients after injury. Alternatively, the increase in the fibrinogen contribution to clot strength after injury may be compensatory for the platelet dysfunction seen after injury. 27, 28 In addition, while we can calculate the relative contributions of fibrinogen and platelets to clot strength, it remains unknown what the importance of each is in ATC. More research is needed to better understand what the critical functional deficit is here. Patients with an overall deficit in clot strength and low FLEVs may be the appropriate target population for fibrinogen containing resuscitation; however, it is unclear whether fibrinogen transfusion will actually correct this deficit. In addition, given that we demonstrated a critical role of FLEVs on outcome, the finding that platelets contribute more to clot after injury than fibrinogen leaves the critical issue of the functional role of platelets unanswered. The functional role of platelets needs to be addressed. In addition, if antiplatelet therapy is of underrecognized importance for thromboprophylaxis, the clinical use of antiplatelet agents after trauma needs significant study.
In conclusion, given our findings that low FLEVs and a low percent contribution of fibrinogen to clot strength on admission were associated with coagulopathy, plasma transfusion, and mortality, early attention to correction of FF deficits may be a useful resuscitation goal. Deeper understanding of the importance of fibrinogen levels during resuscitation may prompt more rapid correction of deficits by earlier, more liberal use of fibrinogen concentrates. Appealingly, as plasma units also contain fibrinogen, a component of the observed benefit of plasma-based resuscitation strategies may also be related to earlier correction of fibrinogen deficits. Both of these issues deserve ongoing study, for which FF TEG will be a critical tool. Concordantly, given that platelets played a greater role in clot strength at all time points after injury, these data confirm recent findings that antiplatelet therapy may be of underrecognized importance to adequate thromboprophylaxis after trauma. 21 In fact, the routine use of heparin-based thromboprophylaxis after trauma, by failing to inhibit platelets, may undertreat the predominant contributor to clot strength at all time points after injury. This issue is of utmost importance to the appropriate treatment of the continued epidemic of hypercoagulability after trauma. Future investigations into hypercoagulability after injury using FF TEG to examine these relative contributions are underway. Indeed, we understand that the coagulation milieu after injury is dynamic and complex and it is in this multivariate context that the optimal role of FF testing will be understood and further studied. 
DISCUSSION
Dr. Ernest E. Moore (Denver, Colorado): While viscoelastic hemostatic assays have been accepted as superior to plasma-based coagulation testing on both sides of the Atlantic, there remains vigorous debate as to the optimal strategy using these devices.
Dr. Kornblith has nicely presented the objective of the TEG functional fibrinogen assay, that is to ascertain the relative contributions of fibrin versus platelets to clot strength reflected in the maximum amplitude.
The ultimate goals, of course, are to guide blood component transfusion to enhance early hemostasis and to deliver optimal prophylaxis for later prevention of venous thromboemblic events.
In sum, the data indicate that in moderately injured patients fibrinogen accounts for 30% of clot strength on admission and this increases to 45% over the ensuing five days.
These data are intriguing but, as with most novel explorations, they perhaps raise more questions than they answer.
One of our challenges in evaluating the coagulation system in the scenario of trauma is to differentiate what is a biomarker of injury severity versus a mediator of adverse events.
Thus, I would like to ask the authors who are clearly experts in trauma-induced coagulopathy to help us understand the clinical implications of their data.
First, it is important to emphasize that fibrinogen accounts for only 20% of clot strength in normal individuals. Interestingly in this study, the closer the fibrinogen contribution was to normal, the greater the association with coagulopathy and transfusion requirements.
However, fibrinogen has been shown to compensate for inadequate platelet function and is an acute phase reactant. Thus, to translate these findings to patient care we need to know the clot strength at the time of the functional fibrinogen assay and the clinical scenario.
That is, are these patients primarily at risk for coagulopathic bleeding or for developing venous thromboemboli? Thus, for this purpose, it would be helpful if the authors analyzed the patients each day, stratified into low, normal or high clot strength.
Furthermore, it would be instructive to determine if the TEG functional fibrinogen correlates with clot strength on each of these days as well as, of course, to platelet function. Do you have any time-dependent data, particularly during the first six hours, to determine the relative impact of platelet versus fibrinogen transfusion to clot strength?
What is your threshold to administer fibrinogen in patients with active bleeding? And in what scenario would you prioritize fibrinogen over fresh frozen plasma?
Your findings, of course, are also very relevant to the other side of the equation, that is, optimizing venous thromboembolism prophylaxis.
Was there a correlation with percent fibrinogen contribution to the incidence of VTE? When would you add anti-platelet therapy to your VTE prophylaxis in the intensive care unit?
And, finally, the role of fibrinogen in venous thromboembolism may extend beyond its interactions with platelets.
For example, recently it has been shown that there is a heparin binding site on the beta chain of fibrinogen that may sequester heparin. Should we be monitoring TEG functional fibrinogen in our ICUs in high risk patients to adjust heparin dosing?
In sum, I congratulate the San Francisco group for another outstanding contribution in elucidating the complex mechanisms driving post-injury coagulopathy and thank the Association for the privilege of the floor.
Dr. Frederick Moore (Gainesville, Florida): By including all patients meeting trauma team activation criteria, you have thrown a pretty wide net which could include substantial number of traumatic brain injured patients. You then make associations with mortality. I'd like to know what type of mortality? Is it due to exsanguination, organ failure or traumatic brain injury? Thank you.
Dr. David P. Blake (Norfolk, Virginia): I, too, enjoyed that paper. I have two questionsVone of which was partially asked by my predecessorVnamely, do you have any data on AIS scores for head and neck? Because I think that may contribute information relevant to this patient population.
And the second question is, do you have any demographics on the premorbid conditions that might be confounders here? For example, were they on antiplatelet therapy or were they on some form of anticoagulation, either standard warfarin therapy or one of the newer anticoagulants, that may confound this picture as well? Thank you very much. I completely agree that the appropriate use of viscoelastic testing in trauma continues to remain unclear and we work toward understanding its appropriate role in the diagnosis and treatment of acute traumatic coagulopathy as well as guidance of thromboprophylaxis. I will address each of your points.
Your first point is that fibrinogen accounts for 20% of clot strength in a normal individual. I think that like all physiologic responses after injury it is difficult to know what functional fibrinogen levels mean in a trauma population relative to a healthy individual. As we all know, the injury response is both biologically and physiologically very different than normal, and when we are characterizing these novel biomarkers, we must first characterize them in our trauma population in relation to who does well versus who does poorly. This is what we have done.
To address your second point, we did stratify the patients into low, normal and high clot strength and then examined differences in outcomes for those with high or low levels of functional fibrinogen. What we found is that the patients with the lowest clot strength (those who bleed) and those who additionally had a low level of functional fibrinogen had significantly worse outcomes. Those patients were more coagulopathic, required more transfusions, and they had higher mortality with worse overall outcomes. However, those with normal or high clot strength, but low functional fibrinogen levels had no major notable differences in outcomes.
Additionally, we did find excellent correlation at each day between functional fibrinogen and clot strength at all time points after injury.
